A randomized clinical trial found that the antidepressant fluvoxamine significantly reduces long COVID-related fatigue, one of the condition’s most persistent and debilitating symptoms, while the diabetes drug metformin showed no benefit. Patients taking fluvoxamine reported steadily improving fatigue and quality-of-life scores over 60 to 90 days, with fewer side effects than those on placebo. The findings are published in Annals of Internal Medicine.
This article was originally published on MedicalXpress.com
